Tempus AI, Inc. (TEM) shares climbed 7.4% to $82.24 as of September 25, 2026, a significant gain from the prior close of $76.59. BestStocks flagged the session as a major change for TEM. Below, we break down what changed for TEM, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
TEM climbed 7.4% to $82.24
Tempus AI rose 10.67% to $68.85 on Tuesday, September 15, 2026 after an upbeat presentation at the Morgan Stanley 24th Annual Global Healthcare Conference, where management highlighted diagnostics pricing, reimbursement and long-term revenue opportunities. The stock, slightly lower premarket, climbed through the day even as the broad market fell.
For Tempus AI, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Strong 7.4% price move with conviction. Weighing against that: Tempus AI, Inc. (TEM) moved -7.74% from $52.47 to $48.41 on 2026-07-20; Tempus AI, Inc. (TEM) moved −6.39% from $57.25 to $53.59 on 2026-07-16. Wall Street's consensus price target sits at $69.90, implying -15.0% downside from $82.24. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality medium (64/100). With earnings roughly 39 days out, the next report is the most likely near-term test of the move.
TEM price reaction
TEM last traded at $82.24, up $5.65 (+7.38%) from the previous close of $76.59. The session traded on 1.6× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $58.74 and $82.24, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Tempus AI, Inc. (TEM)
The consensus analyst price target on Tempus AI, Inc. (TEM) is $69.90, 15.0% below the recent $82.24. Over the past 90 days analysts logged 1 upgrade, 10 maintains, and 0 downgrades. Here is how the bullish and bearish cases on TEM line up.
▲ The bullish case
+1 analyst upgrade in the past 90 days, most recently Piper Sandler to Overweight (2026-09-01).
+Material positive event.
+Strong 7.4% price move with conviction.
▼ The bearish case
−The consensus analyst price target of $69.90 sits 15.0% below the recent $82.24, so the average target sees limited room to run.
−The most bearish analyst target is $50.00 (-39.2%).
−Tempus AI, Inc. (TEM) moved -7.74% from $52.47 to $48.41 on 2026-07-20.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 25, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Tempus AI, Inc. (TEM) moved +10.38% to $80.36 on September 17, 2026, after Piper Sandler upgraded the stock to Overweight from Neutral and raised its price target to $76 from $56. The company also secured up to $9.5 million in federal funding through ARPA-H ADVOCATE for autonomous AI cardiology development, and continued market optimism around its pending Personalis acquisition added to the upward momentum.
Tempus AI surged +10.26% to $68.59 following CEO Eric Lefkofsky's presentation at the Morgan Stanley 24th Annual Global Healthcare Conference today, where management highlighted surging demand in diagnostics and accelerating expansion of its high-margin data licensing business (Seeking Alpha). The gain also reflects positive sentiment from the company's announced initiative to build a 100,000 whole-genome research database paired with clinical outcomes. Volume of 5.9M shares is tracking 0.84x expected levels for this point in the session.
Material / Earnings2026-09-14+5.4%
Tempus AI, Inc. (TEM) moved +7.77% from $57.73 to $62.21 on 2026-09-14 following announcements of a multimodal whole-genome dataset initiative and $9.5 million in ARPA-H ADVOCATE funding to develop autonomous AI for cardiology applications.
Tempus AI shares fell 6.42% to $66.15 amid broader healthcare sector weakness (XLV tracking general Health Care Select Sector SPDF Fund declines) and mixed analyst sentiment following Q2 earnings and the pending $1.5 billion all-stock Personalis acquisition, according to the web catalyst. Volume of 3.3M shares ran 1.31x the expected level for this point in the session.
Material / Earnings2026-08-24-9.0%
Tempus AI, Inc. (TEM) moved -5.57% from $70.08 to $66.17 on 2026-08-24. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Material / Earnings2026-08-21+9.1%
Tempus AI, Inc. (TEM) moved +10.57% on 2026-08-21, driven by positive analyst sentiment, strong Q2 results, and strategic momentum. The company reported improved gross margins, raised full-year guidance, and achieved its first quarterly net profit. Analyst upgrades from firms including BTIG boosted confidence, while the pending acquisition of Personalis to expand into the molecular residual disease market added to investor optimism.
Material / Earnings2026-08-20+8.8%
Tempus AI, Inc. (TEM) moved +7.50% from $62.00 to $66.65 on 2026-08-20. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move coincided with volume 2.9x the 5-day average and a new 30-day high, suggesting technical buying momentum.
Material / Earnings2026-08-19+24.1%
Tempus AI, Inc. (TEM) moved +9.53% from $55.85 to $61.17 on 2026-08-19. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move was accompanied by volume 6.8x the 5-day average and pushed the stock to a new 30-day high.
In-depth TEM event analyses
Permanent, dated analyses of TEM's most significant sessions.
Tempus AI rose 10.67% to $68.85 on Tuesday, September 15, 2026 after an upbeat presentation at the Morgan Stanley 24th Annual Global Healthcare Conference, where management highlighted diagnostics pricing, reimbursement and long-term revenue opportunities. The stock, slightly lower premarket, climbed through the day even as the broad market fell.
How much did TEM stock rise?
TEM gained 7.38% ($5.65) versus the prior close of $76.59, last trading at $82.24 on 1.6× average volume.
When is Tempus AI, Inc.'s next earnings date?
TEM's next earnings report is estimated for 2026-11-03 — about 39 days away.
What is the analyst price target for TEM?
The consensus analyst price target for TEM is $69.90, about 15.0% below the current $82.24. Over the past 90 days, analysts recorded 1 upgrade, 10 maintains, and 0 downgrades.
How BestStocks tracks TEM
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared TEM-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for TEM, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 25, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
